SLFN11 immunostaining of TMAs with 3,300 primary CRCs identified 65 (~2.0%) tumors with focal staining (<10% of tumor nuclei positive), 83 (~2.5%) with patchy (≥10% and <80%), and 51 (~1.5%) with diffuse (≥80%) SLFN11 positivity. This evidence concerns the gene SLFN11 and neoplasm.